CL vs MBX · P/E 34, rev $10.69B vs $1.98B cap
Colgate-Palmolive Company (CL) versus MBX Biosciences, Inc. Common Stock (MBX) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
MBX Biosciences, Inc. Common Stock (MBX) is a biotechnology company listed on NASDAQ.
Latest reported CL revenue for 2026-06-30 was $10.69B. Net income was $1.34B. CL currently screens at market cap $70.88B and trailing P/E 34.3.
MBX does not have a complete income-statement cache yet.
CL currently screens at market cap $70.88B and trailing P/E 34.3. MBX currently screens at market cap $1.98B.
Not investment advice. Open the CL and MBX stock pages for the full models.
Not investment advice.